ARNUITY ELLIPTA Drug Patent Profile

Which patents cover Arnuity Ellipta, and what generic alternatives are available?

Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.

Summary for ARNUITY ELLIPTA

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	2
Patent Applications:	1,594
Drug Prices:	Drug price information for ARNUITY ELLIPTA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARNUITY ELLIPTA
What excipients (inactive ingredients) are in ARNUITY ELLIPTA?	ARNUITY ELLIPTA excipients list
DailyMed Link:	ARNUITY ELLIPTA at DailyMed

See drug prices for ARNUITY ELLIPTA

Recent Clinical Trials for ARNUITY ELLIPTA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Virginia	Phase 2
GlaxoSmithKline	Phase 3

See all ARNUITY ELLIPTA clinical trials

Pharmacology for ARNUITY ELLIPTA

Drug Class	Corticosteroid
Mechanism of Action	Corticosteroid Hormone Receptor Agonists

US Patents and Regulatory Information for ARNUITY ELLIPTA

ARNUITY ELLIPTA is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018		RX	Yes	Yes
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014		RX	Yes	Yes
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014		RX	Yes	Yes

Expired US Patents for ARNUITY ELLIPTA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018	7,101,866
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014	5,873,360
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014	7,629,335

EU/EMA Drug Approvals for ARNUITY ELLIPTA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
GlaxoSmithKline (Ireland) Limited	Avamys	fluticasone furoate	EMEA/H/C/000770Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.	Authorised	no	no	no	2008-01-11
Glaxo Group Ltd.	Alisade	fluticasone furoate	EMEA/H/C/001019Adults, adolescents (12 years and over) and children (6 - 11 years). Alisade is indicated for the treatment of the symptoms of allergic rhinitis.	Withdrawn	no	no	no	2008-10-06

International Patents for ARNUITY ELLIPTA

See the table below for patents covering ARNUITY ELLIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	1305329
Argentina	032361	DERIVADOS DE ANDROSTANO Y SALES Y SOLVATOS DE LOS MISMOS, SU USO PARA LA FABRICACION DE MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN TALES COMPUESTOS, PROCESO PARA LA PREPARACION DE DICHOS COMPUESTOS, E INTERMEDIARIOS UTILES EN LA PREPARACION DE TALES COMPUESTOS
European Patent Office	1305330	DERIVES DE 17-BETA-CARBOTHIOATE-17-ALPHA-ARYLCARBONYLOXYLOXY ANDROSTANE UTILISES COMME ANTI-INFLAMMATOIRES (17.BETA.-CARBOTHIOATE 17.ALPHA.-ARYLCARBONYLOXYLOXY ANDROSTANE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS)

Supplementary Protection Certificates for ARNUITY ELLIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1305329	SPC/GB08/026	United Kingdom		PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
2506844	132018000000341	Italy		PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
2506844	1890025-8	Sweden		PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117

Market Dynamics and Financial Trajectory for ARNUITY ELLIPTA

Last updated: February 10, 2026

ARNUITY ELLIPTA (fluticasone furoate inhalation powder) targets asthma and COPD management. Since its FDA approval in 2014, its market performance reflects shifts in respiratory disease treatment, competitive pressures, and payer dynamics.

Market Position and Sales Performance

Following its launch, ARNUITY gained a steady market share primarily among adult asthma patients. In 2022, its global sales surpassed $700 million, with U.S. prescriptions accounting for approximately 90% of revenue, according to IQVIA data. The drug's sales trajectory aligns with broader asthma and COPD market trends, including increased prevalence and adoption of inhaled corticosteroids (ICS).

The drug's sales growth has plateaued since 2020, attributable to intensified competition from other ICS/LABA combinations such as fluticasone/vilanterol (Breo Ellipta) and mometasone/formoterol (Dulera). The growth rate declined from approximately 10% annually (2018-2019) to low-single digits (2020-2022).

Market Dynamics

1. Competitive Landscape

ARNUITY ELLIPTA competes with multiple inhalers delivering similar therapeutic effects. The inhaled corticosteroid market features dominant devices with established prescriber preference, which limits ARNUITY's expansion. Its differentiation relies on the once-daily dosing, inhaler technology, and patient-specific factors.

2. Patient and Prescriber Trends

The shift toward combination therapies involving ICS and long-acting beta-agonists (LABA) has constrained monotherapy use. Insurance formularies favor combination inhalers, further constraining ARNUITY's prescribing volume when compared with combination products.

3. Regulatory and Reimbursement Environment

Changes in healthcare policies and formulary placement influence access and utilization. Payers demand evidence of superior efficacy or reduced side effects to favor ARNUITY’s position over alternatives. Reimbursement rates for inhalers remain competitive but have tightened in recent years, impacting profitability.

4. Pipeline and Lifecycle Challenges

ARNUITY faces patent protection expiry for primary patents in 2025-2026, risking generic erosion. Biotech players are exploring biosimilars targeting ICS inhalers. GSK has announced efforts to develop next-generation inhalers to extend lifecycle.

Financial Trajectory

1. Revenue Outlook

Analysts project ARNUITY's U.S. revenues to stabilize around $700 million annually through 2025. Post-patent expiry, revenues are expected to decline sharply, assuming no new formulations or indications.

2. Profitability and Margins

Gross margins for ARNUITY hover around 70%. Operating margins are impacted by research, manufacturing, and marketing costs. Patent erosion would pressure margins with the potential emergence of generics.

3. Research and Development

GSK invests in reformulations, combination therapies, and personalized inhalation devices. R&D expenses for respiratory franchise are approximately 10% of total annual R&D, with a focus on inhaler technology.

4. Strategic Moves

GSK’s emphasis on delivering a robust pipeline with new inhaler devices and expanding indications aims to offset market saturation. The development of long-acting combination inhalers with improved delivery systems could extend lifecycle and revenue.

Key Takeaways

• ARNUITY ELLIPTA maintains a stable revenue base of approximately $700 million; growth has plateaued since 2020.

• Competitive pressures from similar ICS inhalers and combination therapies constrain market share expansion.

• Patent expiration around 2025-2026 poses a significant risk; generic erosion will reduce revenues.

• GSK's R&D investments aim to innovate delivery and extend product lifecycle, but near-term revenues remain vulnerable.

• Market access and formulary positioning heavily influence sales, with payer policies trending toward combination therapies.

FAQs

1. When will ARNUITY ELLIPTA face generic competition?
Patent protections are expected to expire between 2025 and 2026, opening the market to biosimilar and generic inhalers.

2. How does ARNUITY compare to competitors in terms of market share?
While it holds a significant share in the adult asthma segment, ARNUITY trails behind combination therapies like Breo Ellipta, which dominates with over $3 billion in sales globally.

3. Are there upcoming formulations or indications that could boost ARNUITY’s sales?
GSK is exploring combination inhalers and new delivery devices, but specific new indications for ARNUITY are not announced.

4. What impact do insurance policies have on ARNUITY sales?
Formulary placements favor combination inhalers, reducing prescriptions of monotherapy ARNUITY unless patient-specific factors favor its use.

5. What strategies could extend ARNUITY’s lifecycle?
Developing next-generation inhalers, expanding indications (e.g., allergic rhinitis), and forming strategic partnerships are potential avenues.

Sources

1. IQVIA. (2022). Top-selling inhaled corticosteroids.
2. GSK Annual Report. (2022). Respiratory franchise analysis.
3. FDA. (2014). Labeling for ARNUITY ELLIPTA.
4. EvaluatePharma. (2022). Respiratory drugs market forecast.
5. IMS Health. (2021). Payer policy shifts in respiratory therapeutics.